MedTrace Logo

Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting

NCT02565615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5115

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。

Conditions

  • Coronary Artery Disease, Hypercholesterolemia, Hypertension

Interventions

OTHER

No intervention

Because this is a non-interventional study, there is no intervention here.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-22
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02565615 on ClinicalTrials.gov